Combination systemic therapies in psoriatic arthritis

Journal of Dermatological Treatment

Volumn 22, Issue 5, 2011, Pages 276-284

  Daly, Meaghan ^a   Alikhan, Ali ^b   Armstrong, April W ^c  

^a College of Physicians and Surgeons ^*  (United States)

^b MACNEAL HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adalimumab; Biologic agents; Combination therapy; Combination treatment; CSA; DMARDs; Etanercept; Golimumab; Infliximab; Methotrexate; NSAIDs; Psoriatic arthritis; Ustekimumab

Indexed keywords

ADALIMUMAB; ALEFACEPT; C REACTIVE PROTEIN; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB;

CELL PROLIFERATION; CLINICAL DECISION MAKING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE ACTIVITY; DISEASE SEVERITY; DNA SYNTHESIS; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; MEDLINE; MESH HEADING; PAIN ASSESSMENT; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; REVIEW; SYSTEMIC THERAPY; TREATMENT RESPONSE; VISUAL ANALOG SCALE;

ARTHRITIS, PSORIATIC; DRUG THERAPY, COMBINATION; HUMANS;

EID: 80053073164     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546631003801601     Document Type: Review

References (45)

1. Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM. Time trends in epidemiology and characteristics of psoriatic arthritis over 3 decades: A population-based study. J Rheumatol. 2009;36:361-367.
2. Gladman DD. Psoriatic arthritis. Dermatol Ther. 2009;22: 40-55.
3. Gelfand JM, Gladman DD, Mease PJ, Smith N, Margolis DJ, Nijsten T, et al. Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol. 2005;53:573.
4. Mease PJ. Psoriatic arthritis assessment and treatment update. Curr Opin Rheumatol. 2009;21:348-355.
5. Kristensen LE, Gulfe A, Saxne T, Geborek P. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: Results from the South Swedish Arthritis Treatment Group register. Ann Rheum Dis. 2008;67: 364-369. (Pubitemid 351281272)
6. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: Development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665-2673. (Pubitemid 44205029)
7. Fitzgerald O, Winchester R. Psoriatic arthritis: From patho-genesis to therapy. Arthritis Res Ther. 2009;11:214.
8. Chan JR, Blumenschein W, Murphy E, Diveu C, Wiekowski M, Abbondanzo S, et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med. 2006;203:2577-2587. (Pubitemid 44833335)
9. Hong K, Chu A, Ludviksson BR, Berg EL, Ehrhardt RO. IL-12, independently of IFN-gamma, plays a crucial role in the pathogenesis of a murine psoriasis-like skin disorder. J Immunol. 1999;162:7480-7491. (Pubitemid 29277728)
10. McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: A 5-yr prospective study. Rheumatology (Oxford). 2003;42:778-783. (Pubitemid 37220911)
11. Gladman DD, Stafford-Brady F, Chang CH, Lewandowski K, Russell ML. Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol. 1990;17:809-812. (Pubitemid 20213507)
12. Husted JA, Gladman DD, Farewell VT, Cook RJ. Health-related quality of life of patients with psoriatic arthritis: A comparison with patients with rheumatoid arthritis. Arthritis Rheum. 2001;45:151-158. (Pubitemid 32954441)
13. Kavanaugh AF, Ritchlin CT. Systematic review of treatments for psoriatic arthritis: An evidence based approach and basis for treatment guidelines. J Rheumatol. 2006;33: 1417-1421. (Pubitemid 44025162)
14. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, et al. Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50:2264-2272. (Pubitemid 38924405)
15. Kavanaugh A, Antoni CE, Gladman D, Wassenberg S, Zhou B, Beutler A, et al. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): Results of radiographic analyses after 1 year. Ann Rheum Dis. 2006; 65:1038-1043. (Pubitemid 44133266)
16. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52:3279-3289. (Pubitemid 41447111)
17. Gottlieb A, Menter A, Mendelsohn A, Shen YK, Li S, Guzzo C, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: Randomised, double-blind, placebo-controlled, crossover trial. Lancet. 2009;373:633-640.
18. Ritchlin CT, Kavanaugh A, Gladman DD, Mease PJ, Helliwell P, Boehncke WH, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis. 2009;68: 1387-1394.
19. Rao P, Knaus EE. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): Cyclooxygenase (COX) inhibition and beyond. J Pharm Pharm Sci. 2008;11:81s-110s.
20. Braun J, Rau R. An update on methotrexate. Curr Opin Rheumatol. 2009;21:216-223.
21. Scarpa R, Peluso R, Atteno M, Manguso F, Spano A, Iervolino S, et al. The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: Results of a pilot randomised 6-month trial with methotrexate. Clin Rheuma-tol. 2008;27:823-826.
22. Madan V, Griffiths CE. Systemic ciclosporin and tacrolimus in dermatology. Dermatol Ther. 2007;20:239-250. (Pubitemid 350029313)
23. Mazzanti G, Coloni L, De Sabbata G, Paladini G. Metho-trexate and cyclosporin combined therapy in severe psoriatic arthritis. A pilot study. Acta Derm Venereol Suppl (Stockh). 1994;186:116-117. (Pubitemid 24208176)
24. Clark CM, Kirby B, Morris AD, Davison S, Zaki I, Emerson R, et al. Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis. Br J Derma-tol. 1999;141:279-282. (Pubitemid 29397996)
25. Fraser AD, van Kuijk AW, Westhovens R, Karim Z, Wakefield R, Gerards AH, et al. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis. Ann Rheum Dis. 2005;64:859-864. (Pubitemid 40733909)
26. Strober BE, Menon K. Alefacept for the treatment of psoriasis and other dermatologic diseases. Dermatol Ther. 2007;20: 270-276. (Pubitemid 350030789)
27. Mease PJ, Gladman DD, Keystone EC. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: Results of a randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2006;54:1638-1645.
28. Mease PJ, Reich K. Alefacept with methotrexate for treatment of psoriatic arthritis: Open-label extension of a randomized, double-blind, placebo-controlled study. J Am Acad Dermatol. 2009;60:402-411.
29. Zhou H, Jang H, Fleischmann RM, Bouman-Thio E, Xu Z, Marini JC, et al. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol. 2007;47: 383-496.
30. Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum. 2009;60:976-986.
31. Spadaro A, Ceccarelli F, Scrivo R, Valesini G. Life-table analysis of etanercept with or without methotrexate in patients with psoriatic arthritis. Ann Rheum Dis. 2008;67:1650-1651.
32. Gladman DD, Mease PJ, Ritchlin CT, Choy EH, Sharp JT, Ory PA, et al. Adalimumab for long-term treatment of pso-riatic arthritis: Forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum. 2007; 56:476-488.
33. Antoni C, Dechant C, Hanns-Martin Lorenz PD, Wendler J, Ogilvie A, Lueftl M, et al. Open-label study of infliximab treatment for psoriatic arthritis: Clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum. 2002;47:506-512. (Pubitemid 35291372)
34. Covelli M, Scioscia C, Iannone F, Lapadula G. Repeated infusions of low-dose infliximab plus methotrexate in psoriatic arthritis: Immediate benefits are not maintained after discontinuation of infliximab. Clin Exp Rheumatol. 2005;23: 145-151. (Pubitemid 40662992)
35. Goedkoop AY, Kraan MC, Picavet DI, de Rie MA, Teunissen MB, Bos JD, et al. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: A prospective single-centre study. Arthritis Res Ther. 2004;6:R326-R334.
36. Provenzano G, Termini A, Le Moli C, Rinaldi F. Efficacy of infliximab in psoriatic arthritis resistant to treatment with disease modifying antirheumatic drugs: An open pilot study. Ann Rheum Dis. 2003;62:680-681. (Pubitemid 36760571)
37. Rinaldi F, Provenzano G, Termini A, Spinello M, La Seta F. Long term infliximab treatment for severe psoriatic arthritis: Evidence of sustained clinical and radiographic response. Ann Rheum Dis. 2005;64:1375-1376. (Pubitemid 41206264)
38. Salvarani C, Cantini F, Olivieri I, Macchioni P, Padula A, Niccoli L, et al. Efficacy of infliximab in resistant psoriatic arthritis. Arthritis Rheum. 2003;49:541-545. (Pubitemid 36988308)
39. Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum. 2005;52:1227-1236. (Pubitemid 40530131)
40. Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, et al. Infliximab improves signs and symptoms of psoriatic arthritis: Results of the IMPACT 2 trial. Ann Rheum Dis. 2005;64:1150-1157. (Pubitemid 41113349)
41. Black RL, O'Brien WM, Vanscott EJ, Auerbach R, Eisen AZ, Bunim JJ. Methotrexate therapy in psoriatic arthritis; Double-blind study on 21 patients. JAMA. 1964;189:743-747.
42. Willkens RF, Williams HJ, Ward JR, Egger MJ, Reading JC, Clements PJ, et al. Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. Arthritis Rheum. 1984;27:376-381. (Pubitemid 14134777)
43. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial. Lancet. 2000;356:385-390. (Pubitemid 30487495)
44. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial. ATTRACT Study Group. Lancet. 1999;354:1932-1939.
45. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998;41:1552-1563. (Pubitemid 28459913)